statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Eyenovia to feature commercial products, Optejet Dispenser at eyecare meetings

Company to demonstrate Mydcombi and Avenova and Share Data for Clobetasol Propionate Ophthalmic Suspension 0.05% at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting...

Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings

Eyenovia, Inc. (NASDAQ:EYEN - Get Free Report) major shareholder Stuart M. Grant bought 100,000 shares of the stock in a transaction on Thursday, March 28th. The stock was purchased at an average...

Eyenovia, Inc. (NASDAQ:EYEN) Major Shareholder Buys $98,000.00 in Stock

Eyenovia, Inc. (NASDAQ:EYEN  Free Report)  Investment analysts at HC Wainwright issued their Q2 2024 EPS estimates for shares of Eyenovia in a research report issued to clients and...

Eyenovia, Inc. (NASDAQ:EYEN) Forecasted to Post Q2 2024 Earnings of ($0.19) Per Share

Eyenovia, Inc. (EYEN) Q4 2023 Earnings Call Transcript...

Eyenovia, Inc. (EYEN) Q4 2023 Earnings Call Transcript

Q4 2023 Eyenovia Inc Earnings Call Transcript

Announced FDA approval of clobetasol propionate ophthalmic suspension 0.05% for post-operative pain and inflammation following ocular surgery Reacquired development and commercialization rights to...

Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion...

NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals

Eyenovia, Inc. (NASDAQ:EYEN  Get Free Report) major shareholder Stuart M. Grant acquired 10,717 shares of the stock in a transaction dated Friday, March 8th. The stock was acquired at an...

Stuart M. Grant Purchases 10,717 Shares of Eyenovia, Inc. (NASDAQ:EYEN) Stock

Company to host an investor conference call and webcast at 4:30pm EDTNEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic pharmaceutical...

Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th

Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.

Volume	2.48M
52-Wk High	$5.29
52-Wk Low	$0.501

EYEN Eyenovia Inc

About

Feed

News

Earnings

Fundamentals